Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Biometals

• Publication date

  1994-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00144120PMID 7812111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells.

  1993cited by this paper
• A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload.

  1993cited by this paper
• Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.

  1992cited by this paper
• Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: an ESR spin-trapping investigation.

  1991cited by this paper
• Rapid induction of hepatic fibrosis in the gerbil after the parenteral administration of iron‐dextran complex

  1991cited by this paper
• Theory and Practice of Histological Techniques

  1990cited by this paper
• Factors Involved in the Regulation of Iron Transport through Reticuloendothelial Cells

  1990cited by this paper
• Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.

  1990influential reference
• The development of iron chelating drugs.

  1989cited by this paper
• Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy.

  1989cited by this paper
• 2 The development of iron chelating drugs

  1989cited by this paper
• Iron metabolism in thalassemia.

  1988cited by this paper
• Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.

  1987cited by this paper
• Pathology of dietary carbonyl iron overload in rats.

  1987cited by this paper
• Heterogeneity and origins of the alpha-thalassemias.

  1987cited by this paper
• In vivo evaluation of hydroxypyridone iron chelators in a mouse model.

  1987cited by this paper
• Ultrastructural observations in the carbonyl iron-fed rat, an animal model for hemochromatosis

  1987cited by this paper
• Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis

  1986cited by this paper
• Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

  1986cited by this paper
• Nonspecific serum iron in thalassemia: Quantitation and chemical reactivity

  1979cited by this paper
• Iron in the heart. Etiology and clinical significance.

  1971cited by this paper

• Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations

  2019cites this paper
• Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse

  2016cites this paper
• Experimental animal model to study iron overload and iron chelation and review of other such models.

  2015cites this paper
• Iron sufficient to cause hepatic fibrosis and ascites does not cause cardiac arrhythmias in the gerbil.

  2009cites this paper
• Acetaminophen protects against iron-induced cardiac damage in gerbils.

  2007cites this paper
• Iron-loaded cardiac myocytes stimulate cardiac myofibroblast DNA synthesis

  2006cites this paper
• Liver Fibrosis and Iron Levels During Long-Term Deferiprone Treatment of Thalassemia Major Patients

  2006cites this paper
• Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.

  2006cites this paper
• Iron Chelation Suppresses Ferritin Upregulation and Attenuates Vascular Dysfunction in the Aorta of Angiotensin II–Infused Rats

  2005cites this paper
• Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease States.

  2005cites this paper
• Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia

  2005cites this paper
• Brittenham et al response

  2004cites this paper
• Role of deferiprone in chelation therapy for transfusional iron overload.

  2003cites this paper
• Effects of retinol and hepatocyte-conditioned medium on cultured rat hepatic stellate cells.

  2003cites this paper
• Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.

  2003cites this paper
• Genetic regulation of cell function in response to iron overload or chelation.

  2003cites this paper
• The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.

  2002cites this paper
• Long term deferiprone chelation therapy.

  2002cites this paper
• Orally active iron chelators.

  2002cites this paper
• Bimodal cardiac dysfunction in an animal model of iron overload.

  2002cites this paper
• Secondary iron overload.

  2001cites this paper
• Safety profile of the oral iron chelator deferiprone: a multicentre study

  2000cites this paper
• Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts.

  2000cites this paper
• Cellular Uptake and Release of Two Contrasting Iron Chelators

  1999cites this paper
• Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease.

  1999cites this paper
• The beta-thalassemias.

  1999cites this paper
• Thalassaemia: clinical management.

  1998cites this paper
• Long‐Term Trials of Deferiprone in Cooley's Anemia a

  1998cites this paper
• Iron chelation with oral deferiprone in patients with thalassemia.

  1998cites this paper
• Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

  1998cites this paper
• Iron chelation with oral deferiprone in patients with thalassemia.

  1998cites this paper
• The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells.

  1998cites this paper
• HBED: A potential alternative to deferoxamine for iron-chelating therapy.

  1998cites this paper
• Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats.

  1997cites this paper